Windward Capital Management Co. CA decreased its holdings in shares of Allergan plc (NYSE:AGN) by 2.5% during the third quarter, HoldingsChannel reports. The firm owned 3,213 shares of the company’s stock after selling 84 shares during the period. Windward Capital Management Co. CA’s holdings in Allergan were worth $541,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of AGN. First Trust Advisors LP increased its holdings in shares of Allergan by 124.3% in the 1st quarter. First Trust Advisors LP now owns 378,941 shares of the company’s stock valued at $55,481,000 after acquiring an additional 210,004 shares during the last quarter. Meridian Wealth Management LLC bought a new position in Allergan during the 1st quarter worth $62,000. Marshall Wace North America L.P. bought a new position in Allergan during the 1st quarter worth $452,000. Clearbridge Investments LLC grew its stake in Allergan by 8.6% during the 1st quarter. Clearbridge Investments LLC now owns 9,167,006 shares of the company’s stock worth $1,342,141,000 after buying an additional 726,688 shares during the last quarter. Finally, Diversified Trust Co grew its stake in Allergan by 62.5% during the 1st quarter. Diversified Trust Co now owns 7,817 shares of the company’s stock worth $1,144,000 after buying an additional 3,006 shares during the last quarter. 80.52% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts recently commented on AGN shares. Cantor Fitzgerald upped their price objective on Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Sanford C. Bernstein downgraded Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price objective for the company. in a research note on Tuesday, July 16th. Svb Leerink restated a “market perform” rating and set a $188.00 price objective (down from $217.00) on shares of Allergan in a research note on Thursday, July 18th. UBS Group upped their price objective on Allergan from $172.00 to $189.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th. Finally, Leerink Swann downgraded Allergan from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $217.00 to $188.00 in a research note on Thursday, July 18th. One analyst has rated the stock with a sell rating, sixteen have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $179.15.
Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.34 by $0.04. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company had revenue of $4.09 billion during the quarter, compared to analysts’ expectations of $3.93 billion. During the same quarter in the prior year, the business posted $4.42 earnings per share. The company’s revenue for the quarter was down .8% compared to the same quarter last year. Equities analysts expect that Allergan plc will post 16.68 earnings per share for the current fiscal year.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Further Reading: What does an outperform rating mean?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.